Insulin Regulation Disorders Causing Diabetes Mellitus: A Hormonal Perspective

Insulin Regulation Disorders Causing Diabetes Mellitus: A Hormonal Perspective

Diabetes mellitus, a chronic metabolic disorder characterised by high blood glucose levels (hyperglycaemia), affects millions worldwide. The condition can be categorised into two main types: Type 1 and Type 2.

In Type 1 diabetes, the body's immune system attacks cells that produce insulin in the pancreas, leading to insulin deficiency. In contrast, Type 2 diabetes occurs when the body becomes resistant to insulin or doesn't produce enough insulin.

Recent advances in targeted therapeutic approaches for both Type 1 (T1D) and Type 2 (T2D) diabetes encompass several promising areas.

For T1D, cutting-edge stem cell treatments focus on repairing or replacing damaged pancreatic beta cells to restore insulin production. Innovations include induced pluripotent stem cells, mesenchymal stem cells, pancreatic islet organoids, and 3D-bioprinted organoids. Clinical trials have demonstrated restored insulin production and reduced insulin dependence in patients.

Immunotherapies aim to halt or reduce autoimmune destruction of beta cells. Examples include abatacept and rituximab, tested individually and in combination, to delay disease progression. Baricitinib, a JAK1/2 inhibitor, has shown promise by modulating immune cell activity, thereby protecting beta cells and improving endogenous insulin production.

Advanced closed-loop systems, or artificial pancreas, have improved the efficacy, reliability, and user-friendliness of diabetes management, predicting and preventing hypoglycaemia.

Incretin-based therapies, traditionally used in T2D, are being explored in T1D for their potential to reduce glycemic variability, improve insulin sensitivity, and provide cardiovascular and renal benefits, especially in patients with residual beta cell function or obesity.

For T2D, the advances noted around incretin-based therapies remain central, delivering glycemic control with additional cardiometabolic benefits. Stem cell therapy research also extends to T2D, where regenerative approaches and immunomodulation may help address beta cell dysfunction and insulin resistance.

Challenges and future directions include overcoming immune rejection and safety issues with stem cell therapies, achieving effective and sustained immune modulation in T1D, and validating cardiovascular and renal benefits of new pharmacotherapies in diverse patient populations.

Combining immune therapies and personalised medicine approaches leveraging artificial intelligence and bioprinted organoids are being pursued to enhance outcomes and address patient heterogeneity.

In summary, current research is rapidly advancing toward more targeted, disease-modifying treatments that go beyond glycemic control, aiming to restore endogenous insulin function and reduce complications in both T1D and T2D.

Treatment for T2D usually begins with lifestyle changes like healthy eating, regular physical activity, and weight loss. Digital health tools, such as continuous glucose monitors, insulin pumps, and mobile health apps, are transforming diabetes self-management by tracking glucose levels and insulin use.

Understanding the complex interplay between multiple hormones, such as glucagon, cortisol, growth hormone, and adipokines, is essential due to their effects on glucose metabolism and the complex hormonal network that maintains energy balance in the body.

Due to rising childhood obesity rates, an increasing number of children and adolescents are being diagnosed with diabetes. Disruptions to the system that regulates blood sugar can have widespread effects and affect multiple areas of the body.

Diabetes is diagnosed through blood tests, including measuring fasting blood glucose, HbA1c, oral glucose tolerance tests, and autoantibody screening for Type 1 diabetes.

In a healthy person, insulin is produced by the beta cells of the pancreas in response to rising blood glucose levels after meals. Problems with insulin can involve insufficient production or resistance to insulin.

People with T1D must take insulin injections for life, often given as a combination of long-acting and short-acting insulin. People with T2D often have abnormal levels of other hormones, such as glucagon, which can further raise blood sugar levels.

Metformin is a medication used in the treatment of T2D. Research is being done on personalised approaches to treating diabetes based on individual differences in genetics, hormone levels, and metabolic profiles.

Ongoing research is focused on developing better treatments for diabetes, such as artificial pancreas systems, immunotherapies, stem cell therapy, gene therapy, smart insulin formulations, and digital health tools.

[1] Diabetes Technology Society. (2021). Artificial Pancreas Systems. Retrieved from https://www.diabetes.org/technology/artificial-pancreas-systems

[2] Diabetes UK. (2021). Incretin-based therapies. Retrieved from https://www.diabetes.org.uk/guide-to-diabetes/treatment-and-care/medicines/incretin-based-therapies

[3] Juvenile Diabetes Research Foundation. (2021). Immune Therapies. Retrieved from https://www.jdrf.org/disease-information/treatment/immune-therapies/

[4] National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Stem Cell Transplantation. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/treatment/stem-cell-transplantation

[5] ViaCyte. (2021). PCF Challenge Awards. Retrieved from https://viacyte.com/research/pcf-challenge-awards/

1. Emerging immunotherapies, such as abatacept, rituximab, and baricitinib, aim to halt or reduce autoimmune destruction of beta cells in Type 1 diabetes (T1D), potentially delaying disease progression.
2. In Type 2 diabetes (T2D), recent advancements in medical-conditions like incretin-based therapies provide glycemic control with additional cardiometabolic benefits, while ongoing research investigates regenerative stem cell approaches to address beta cell dysfunction and insulin resistance.
3. The use of medication, like Metformin in T2D treatment, is evolving towards personalised therapies based on genetics, hormone levels, and metabolic profiles, offering improved health outcomes for diabetes patients.
4. Chronic-diseases like diabetes are associated with complications, such as weight loss resistance and high blood pressure, which necessitate a focus on holistic health strategies, including lifestyle changes and weight management for effective disease management.
5. Developments in science, particularly spiraling advances in technology like artificial pancreas systems, smart insulin formulations, and digital health tools, are revolutionising diabetes management and helping diabetes patients achieve better health and wellness outcomes.

Read also: